Jendo Innovations, a Sri Lankan biomedical startup, has secured fresh investment for its AI-powered heart device capable of detecting early-stage cardiovascular disease in just 15 minutes.
Sri Lanka’s Jendo secures funding for AI-powered heart disease detection
Jendo Innovations, a leading Sri Lankan biomedical startup, has achieved a breakthrough with its AI-powered heart device that can detect early signs of cardiovascular disease within 15 minutes. The company recently closed a new investment round, backed mainly by US investors, boosting its valuation to several million dollars and marking a pivotal moment in its growth journey.
Founded over a decade ago as a university project, Jendo has evolved into a globally recognised innovator in medical technology. The company’s heart device addresses one of the world’s most pressing health issues—cardiovascular disease, which claims nearly 18 million lives every year. Unlike traditional diagnostic methods such as angiograms and stress tests that are invasive and costly, Jendo’s solution offers a rapid, non-invasive, and accurate assessment that empowers patients with early preventive care.
The company, led by Chairman and CEO Keerthi Kodithuwakku, alongside Directors Vinod Samarawicrama and Heminda Jayaweera, is preparing for entry into the US market with FDA approval processes already in motion. A Series A funding round is planned for early next year to support further global expansion and regulatory milestones.
Jendo’s progress has been reinforced by strategic partnerships with Planet43, the Luxembourg-based Accelerator, Stanford Seeds Accelerator, and John Keells X Accelerator. These collaborations have guided the company through international regulatory frameworks and global market strategies.
At the core of the innovation is machine learning and cloud-based analysis that studies endothelial cells in blood vessels to detect “endothelial dysfunction,” the earliest detectable stage of heart disease. Tested across thousands of patients in hospitals and diagnostic labs, the device has consistently shown high accuracy, securing patents in Sri Lanka, Japan, and the United States. Results have also been presented at the prestigious IEEE Biomedical Engineering World Congress.
Over the years, Jendo has been recognised with numerous awards and accolades. From being named a Top 10 Innovation at the Cambridge Innovations Forum in 2017 to winning MetLife Insurance’s CEO Award in 2018, the company has continually proven its global credibility. More recently, Jendo’s leadership has shared insights on global platforms such as the WIPO Conference on IP and Artificial Intelligence and the ITU-WHO Global Initiative for AI for Health. Locally, it was named Innovator of the Year in 2024 and secured GMP certification from the National Medicines Regulatory Authority.
The device’s scalability is one of its strongest features, enabling advanced cardiac screening to reach both urban hospitals and rural clinics where access to specialised diagnostics is limited. This approach could fundamentally shift healthcare from reactive treatments to proactive prevention, helping to reduce the burden of heart disease worldwide.
With FDA approvals underway and fresh funding secured, Jendo Innovations is well-positioned to take Sri Lankan biomedical technology to the global stage. Its AI heart device stands as a symbol of how local innovation can deliver solutions with global impact, offering hope for a future where early detection makes heart attacks preventable rather than inevitable.